CA2249195A1 - Immunoglobin-like domains with increased half lives - Google Patents

Immunoglobin-like domains with increased half lives Download PDF

Info

Publication number
CA2249195A1
CA2249195A1 CA002249195A CA2249195A CA2249195A1 CA 2249195 A1 CA2249195 A1 CA 2249195A1 CA 002249195 A CA002249195 A CA 002249195A CA 2249195 A CA2249195 A CA 2249195A CA 2249195 A1 CA2249195 A1 CA 2249195A1
Authority
CA
Canada
Prior art keywords
fcrn
igg
hinge
binding
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002249195A
Other languages
English (en)
French (fr)
Inventor
Elizabeth Sally Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CA2249195A1 publication Critical patent/CA2249195A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002249195A 1996-03-18 1997-03-03 Immunoglobin-like domains with increased half lives Abandoned CA2249195A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1356396P 1996-03-18 1996-03-18
US60/013,563 1996-03-18

Publications (1)

Publication Number Publication Date
CA2249195A1 true CA2249195A1 (en) 1997-09-25

Family

ID=21760590

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002249195A Abandoned CA2249195A1 (en) 1996-03-18 1997-03-03 Immunoglobin-like domains with increased half lives

Country Status (7)

Country Link
EP (1) EP0904107B1 (enExample)
JP (1) JP4046354B2 (enExample)
AT (1) ATE279947T1 (enExample)
AU (1) AU728657B2 (enExample)
CA (1) CA2249195A1 (enExample)
DE (1) DE69731289D1 (enExample)
WO (1) WO1997034631A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115380217A (zh) * 2020-04-08 2022-11-22 豪夫迈·罗氏有限公司 大分子非特异性清除测定

Families Citing this family (819)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
CA2341029A1 (en) * 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9824632D0 (en) * 1998-11-10 1999-01-06 Celltech Therapeutics Ltd Biological compounds
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) * 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) 1999-08-09 2011-10-12 メルク パテント ゲーエムベーハー 複合サイトカイン−抗体複合体
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU2154401A (en) 1999-11-12 2001-05-30 Merck Patent Gmbh Erythropoietin forms with improved properties
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2407083A1 (en) * 2000-04-21 2001-11-01 Amgen Inc. Apo-ai/aii peptide derivatives
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ATE361318T1 (de) 2000-05-12 2007-05-15 Amgen Inc Polypeptiden, die die april-vermittelte aktivierung von t-und b-zellen hemmen
US7517526B2 (en) 2000-06-29 2009-04-14 Merck Patent Gmbh Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
JP4434580B2 (ja) 2000-11-28 2010-03-17 メディミューン，エルエルシー 予防及び治療のために抗ｒｓｖ抗体を投与／処方する方法
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
AU2008201419C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
PL205352B1 (pl) 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
AU2002342669C1 (en) 2001-05-11 2010-10-07 Amgen, Inc. Peptides and related molecules that bind to TALL-1
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
DK1454138T3 (da) 2001-12-04 2012-02-13 Merck Patent Gmbh Immunocytokiner med moduleret selektivitet
US7662925B2 (en) 2002-03-01 2010-02-16 Xencor, Inc. Optimized Fc variants and methods for their generation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US8187593B2 (en) 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8530627B2 (en) 2002-08-14 2013-09-10 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7365168B2 (en) 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL211180B1 (pl) 2002-12-17 2012-04-30 Merck Patent Gmbh Białko fuzyjne typu przeciwciało-IL2, wektor zawierający sekwencję kwasów nukleinowych kodujących takie białko, kompozycja farmaceutyczna zawierająca takie białko fuzyjne oraz jego zastosowania do wytwarzania leków
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
JP4685764B2 (ja) * 2003-04-10 2011-05-18 アボット バイオセラピューティクス コーポレイション 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変
AU2004229501B2 (en) 2003-04-11 2011-08-18 Medimmune, Llc Recombinant IL-9 antibodies and uses thereof
US9051373B2 (en) 2003-05-02 2015-06-09 Xencor, Inc. Optimized Fc variants
SI1624891T2 (sl) 2003-05-06 2013-09-30 Biogen Idec Hemophilia Inc. Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
WO2005012530A2 (en) 2003-07-25 2005-02-10 Amgen Inc. Antagonists and agonists of ldcam and methods of use
NZ545776A (en) 2003-08-22 2009-05-31 Biogen Idec Inc Improved antibodies having altered effector function and methods for making the same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
US20070148170A1 (en) 2005-10-03 2007-06-28 Desjarlais John R Fc Variants With Optimized Fc Receptor Binding Properties
CA2543484C (en) 2003-10-27 2014-02-04 Amgen Inc. Modulation of immune response to an immunogen with ctla-4 and tnfbp
ES2456325T3 (es) 2003-11-06 2014-04-22 Seattle Genetics, Inc. Compuestos de monometilvalina capaces de conjugación con ligandos
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
EP2239273B1 (en) 2003-11-13 2013-10-09 Hanmi Science Co., Ltd. A pharmaceutical composition comprosing an immunoglobulin fc as a carrier
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
EP1699822B1 (en) 2003-12-30 2008-04-23 MERCK PATENT GmbH Il-7 fusion proteins with antibody portions, their preparation and their use
DK1699821T3 (da) 2003-12-31 2012-07-16 Merck Patent Gmbh Fc-ERYTHROPOIETIN-FUSIONSPROTEIN MED FORBEDREDE FARMAKOKINETIKKER
SI1704166T1 (sl) 2004-01-07 2015-06-30 Novartis Vaccines And Diagnostics, Inc. M-scf specifiäśno monoklonsko protitelo in uporabe le-tega
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
JP2008504012A (ja) 2004-01-28 2008-02-14 シントニックス・ファーマシューティカルズ・インコーポレーテッド 不妊治療のためのへテロ二量体卵胞刺激ホルモン−Ｆｃ（ＦＳＨ−Ｆｃ）融合タンパク質
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
KR101297146B1 (ko) 2004-05-10 2013-08-21 마크로제닉스, 인크. 인간화 ＦｃγＲＩＩＢ 특이적 항체 및 그의 사용 방법
ES2607804T3 (es) 2004-05-13 2017-04-04 Icos Corporation Quinazolinones como inhibidores de la fosfatidilinositol humana 3-quinasa delta
WO2006009901A2 (en) 2004-06-18 2006-01-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
MX2007000216A (es) 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
US20150010550A1 (en) 2004-07-15 2015-01-08 Xencor, Inc. OPTIMIZED Fc VARIANTS
KR20070047327A (ko) 2004-07-26 2007-05-04 비오겐 아이덱 엠에이 아이엔씨. 항-ｃｄ154 항체
EA012464B1 (ru) 2004-08-04 2009-10-30 Эпплайд Молекьюлар Эволюшн, Инк. Антитело против cd20 и его применение
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
WO2007024249A2 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
BRPI0517837A (pt) 2004-11-12 2008-10-21 Xencor Inc variantes fc com ligação alterada a fcrn
DE602005020837D1 (de) 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
WO2006072620A1 (en) 2005-01-05 2006-07-13 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
JP5838021B2 (ja) 2005-04-15 2015-12-24 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディとその使用
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US7833979B2 (en) 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
WO2006122079A1 (en) 2005-05-06 2006-11-16 Zymogenetics, Inc. Il-31 monoclonal antibodies and methods of use
ES2827247T3 (es) 2005-06-21 2021-05-20 Xoma Us Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
DK1912671T3 (da) 2005-07-18 2017-11-27 Seattle Genetics Inc Beta-glucuronid-linker-lægemiddelkonjugater
EP1913027B1 (en) 2005-07-28 2015-03-04 Novartis AG M-csf specific monoclonal antibody and uses thereof
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods for their use
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007044616A2 (en) 2005-10-06 2007-04-19 Xencor, Inc. Optimized anti-cd30 antibodies
EP1933873A4 (en) 2005-10-13 2009-12-02 Human Genome Sciences Inc METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATIENTS WITH POSITIVE DISEASES FOR SELF-ANTIBODIES
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
JP5322653B2 (ja) 2005-11-28 2013-10-23 ザイモジェネティクス， インコーポレイテッド Ｉｌ−２１アンタゴニスト
US20090286962A1 (en) 2005-12-20 2009-11-19 Woolven Benjamin P Chimeric antibodies with part new world primate binding regions
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
BRPI0707425A2 (pt) 2006-02-01 2011-05-03 Arana Therapeutics Ltd construção de anticorpo de domìnio, molécula isolada de ácido nucleico, composição farmacêutica, e, métodos para detectar tnf-alfa humano em uma amostra, e para tratar um distúrbio
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US8592149B2 (en) 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
ES2489646T3 (es) 2006-05-26 2014-09-02 Macrogenics, Inc. Anticuerpos humanizados específicos a Fc gamma RIIB y sus métodos de uso
EP2815764A1 (en) 2006-06-14 2014-12-24 Macrogenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ATE555383T1 (de) * 2006-06-22 2012-05-15 Novo Nordisk As Lösliche heterodimere rezeptoren und ihre verwendung
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
AT503861B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von t-zell-rezeptoren
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009001293A (es) 2006-08-03 2009-02-11 Astrazeneca Ab Anticuerpos dirigidos a (v(6 y usos de los mismos.
BRPI0715332A2 (pt) 2006-08-04 2013-10-08 Novartis Ag Anticorpo, métodos de triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 útil para o tratamento de câncer, de alterar sistemicamente os anticorpos e triar um anticorpo quanto ao domínio extracelular de uma proteína ephb3 para o tratamento de câncer, de tratar um paciente que sofre de câncer, de alvejar uma célula tumoral que expressa epbh3, e de usar a célula hospedeira, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, composição farmacêutica, e kit.
SI2511301T1 (en) 2006-08-04 2018-05-31 MedImmune Limited, Human antibodies to ERBB 2
PT2059536E (pt) 2006-08-14 2014-04-14 Xencor Inc Anticorpos otimizados que visam cd19
NZ596834A (en) 2006-08-18 2013-06-28 Novartis Ag Prlr-specific antibody and uses thereof
KR101374983B1 (ko) 2006-08-28 2014-03-17 라 졸라 인스티튜트 포 앨러지 앤드 이뮤놀로지 길항성 인간 ｌｉｇｈｔ-특이적 인간 모노클로날 항체를 포함하는 제약 조성물
EP2594586B1 (en) 2006-09-01 2014-08-27 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
AU2007299843B2 (en) 2006-09-18 2012-03-08 Xencor, Inc Optimized antibodies that target HM1.24
JP2010506842A (ja) 2006-10-16 2010-03-04 メディミューン，エルエルシー 半減期が短縮された分子、その組成物および使用
AR063384A1 (es) 2006-10-25 2009-01-28 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
HU0700534D0 (en) 2006-11-24 2007-10-29 Mezoegazdasagi Biotechnologiai Transgenic animal with enhanced immune response and method for the preparation thereof
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
EP2101816B1 (en) 2006-12-07 2013-08-14 Novartis AG Antagonist antibodies against ephb3
WO2008140603A2 (en) 2006-12-08 2008-11-20 Macrogenics, Inc. METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING
WO2008077145A2 (en) 2006-12-20 2008-06-26 Xoma Technology Ltd. Treatment of il-1-beta related diseases
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
CA2682292A1 (en) 2007-03-30 2008-10-09 Medimmune, Llc Aqueous formulation comprising an anti-human interferon alpha antibody
WO2008136694A1 (en) 2007-05-04 2008-11-13 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
AU2008253720B2 (en) 2007-05-11 2014-01-16 Altor Bioscience Corporation Fusion molecules and IL-15 variants
CN101848732B (zh) 2007-05-14 2013-06-05 米迪缪尼有限公司 降低嗜酸性粒细胞水平的方法
MX2009012609A (es) 2007-05-22 2009-12-07 Amgen Inc Composiciones y metodos para producir proteinas de fusion bioactivas.
CA2693053C (en) 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
PL3241842T3 (pl) 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
NZ597885A (en) 2007-07-26 2013-08-30 Amgen Inc Modified lecithin-cholesterol acyltransferase enzymes
EP2069401A4 (en) 2007-07-31 2011-02-23 Medimmune Llc MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
PE20120259A1 (es) 2007-08-09 2012-04-04 Boehringer Ingelheim Int Anticuerpos anti-cd37
KR20140117638A (ko) 2007-08-29 2014-10-07 사노피 인간화된 항-ｃｘｃｒ5 항체, 이의 유도체 및 이들의 용도
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
EP2195341B1 (en) 2007-09-26 2017-03-22 UCB Biopharma SPRL Dual specificity antibody fusions
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
ES2572231T3 (es) 2007-12-07 2016-05-30 Zymogenetics Inc Anticuerpos monoclonales anti-IL-21 humana
JP5744522B2 (ja) 2007-12-07 2015-07-08 ザイモジェネティクス， インコーポレイテッド Ｉｌ−３１に特異的なヒト化抗体分子
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
AU2008343085B2 (en) 2007-12-20 2015-03-12 Xoma (Us) Llc Methods for the treatment of gout
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
US8609105B2 (en) 2008-03-18 2013-12-17 Seattle Genetics, Inc. Auristatin drug linker conjugates
HRP20161050T1 (hr) 2008-04-02 2016-11-18 Macrogenics, Inc. Her2/neu specifična protutijela i postupci njihovog korištenja
CA2720365C (en) 2008-04-02 2019-01-15 Macrogenics, Inc. Bcr-complex-specific antibodies and methods of using same
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
EP2307456B1 (en) 2008-06-27 2014-10-15 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
NZ600622A (en) 2008-08-05 2013-12-20 Novartis Ag Compositions and methods for antibodies targeting complement protein c5
CN102282172B (zh) 2008-09-07 2014-02-19 台湾醣联生技医药股份有限公司 抗伸展的ⅰ型鞘糖脂抗体、其衍生物以及用途
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
WO2010045193A1 (en) * 2008-10-14 2010-04-22 Genentech, Inc. Immunoglobulin variants and uses thereof
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102271683B (zh) 2008-11-13 2014-07-09 吉里德卡利斯托加公司 恶性血液病的治疗
WO2010068722A1 (en) 2008-12-12 2010-06-17 Medimmune, Llc Crystals and structure of a human igg fc variant with enhanced fcrn binding
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010108153A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof
AU2010229968A1 (en) 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
EP2421536B1 (en) 2009-04-20 2015-08-26 Gilead Calistoga LLC Methods of treatment for solid tumors
EP3009454A3 (en) 2009-04-20 2016-10-19 Oxford Bio Therapeutics Limited Antibodies specific to cadherin-17
EA201171259A1 (ru) 2009-04-22 2012-05-30 Мерк Патент Гмбх Антительные гибридные белки с модифицированными сайтами связывания fcrn
JP2012525847A (ja) 2009-05-05 2012-10-25 アムジエン・インコーポレーテツド Ｆｇｆ２１変異体およびその使用
BRPI1011404B1 (pt) 2009-05-05 2022-05-03 Amgen Inc Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
WO2010146584A1 (en) 2009-06-15 2010-12-23 Biokine Therapeutics Ltd. Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer
CA2765688A1 (en) 2009-06-19 2010-12-23 Medimmune, Llc Protease variants
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
JP5883384B2 (ja) 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
US8568719B2 (en) 2009-08-13 2013-10-29 Crucell Holland B.V. Antibodies against human respiratory syncytial virus (RSV) and methods of use
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US20110189183A1 (en) 2009-09-18 2011-08-04 Robert Anthony Williamson Antibodies against candida, collections thereof and methods of use
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CA2772945A1 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CA2776385C (en) 2009-10-07 2019-04-09 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2470569A1 (en) 2009-10-13 2012-07-04 Oxford Biotherapeutics Ltd. Antibodies against epha10
WO2011056073A2 (en) 2009-11-04 2011-05-12 Erasmus University Medical Center Rotterdam Novel compounds for modulating neovascularisation and methods of treatment using these compounds
JP2013511279A (ja) 2009-11-20 2013-04-04 アムジエン・インコーポレーテツド 抗Ｏｒａｉ１抗原結合蛋白及びその使用
DK2504364T3 (da) 2009-11-24 2017-11-06 Medimmune Ltd Målrettede bindemidler mod b7-h1
UA109888C2 (uk) 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
KR101312829B1 (ko) 2009-12-30 2013-09-27 한화엘앤씨 주식회사 ＨＯ-1 유전자 및 ＴＮＦＲ1-Ｆｃ 유전자를 동시에 발현하는 형질전환 돼지 및 그의 제조 방법
WO2011091078A2 (en) 2010-01-19 2011-07-28 Xencor, Inc. Antibody fc variants with enhanced complement activity
ME03447B (me) 2010-03-04 2020-01-20 Macrogenics Inc Anтitela reakтivna sa b7-нз, njihovi imunološki akтivni fragmenтi i upotreba
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AR081755A1 (es) 2010-04-02 2012-10-17 Hanmi Holdings Co Ltd Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
JP2013528360A (ja) 2010-04-09 2013-07-11 アムジェン インコーポレイテッド Ｂｔｎｌ９タンパク質、核酸および抗体ならびにそれらの使用
MX2012011986A (es) 2010-04-15 2013-03-05 Amgen Inc RECEPTOR FGF HUMANO Y PROTEINAS ENLAZADAS A ß-KLOTHO.
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
PH12012502193A1 (en) 2010-05-06 2021-08-09 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
AU2011258425B2 (en) 2010-05-27 2015-12-10 Merck Sharp & Dohme Llc Method for preparing antibodies having improved properties
KR20190104442A (ko) 2010-07-09 2019-09-09 바이오버라티브 테라퓨틱스 인크. 인자 iｘ 폴리펩티드 및 이들의 사용 방법
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CU24094B1 (es) 2010-08-20 2015-04-29 Novartis Ag Anticuerpos para el receptor 3 del factor de crecimiento epidérmico(her3)
US20130224191A1 (en) 2010-08-27 2013-08-29 Robert A. Stull Notum protein modulators and methods of use
SG188328A1 (en) 2010-09-03 2013-04-30 Stem Centrx Inc Novel modulators and methods of use
WO2012040323A2 (en) 2010-09-21 2012-03-29 Altor Bioscien Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
MX360946B (es) 2010-09-22 2018-10-29 Amgen Inc Star Inmunoglobulinas portadoras y usos de las mismas.
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
JP6167040B2 (ja) 2010-11-05 2017-07-19 ザイムワークス，インコーポレイテッド Ｆｃドメイン中に突然変異を有する、安定したヘテロ二量体抗体の設計
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US20140302034A1 (en) 2010-12-08 2014-10-09 Stem Centrx, Inc. Novel modulators and methods of use
ES2720136T3 (es) 2010-12-22 2019-07-18 Teva Pharmaceuticals Australia Pty Ltd Anticuerpo modificado con semivida mejorada
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
KR101276801B1 (ko) 2011-01-21 2013-06-19 한화엘앤씨 주식회사 ｓＴＮＦＲ1-Ｆｃ 유전자를 발현하는 형질전환 돼지 및 이의 용도
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
MX352889B (es) 2011-02-25 2017-12-13 Chugai Pharmaceutical Co Ltd Anticuerpo de fc especifico para fcyriib.
EP3235508B1 (en) 2011-03-16 2020-12-30 Sanofi Compositions comprising a dual v region antibody-like protein
SG10201601789TA (en) 2011-03-16 2016-04-28 Amgen Inc Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
EP3896083B1 (en) 2011-04-13 2023-03-01 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
EP2714732A4 (en) 2011-05-25 2014-12-10 Merck Sharp & Dohme PROCESS FOR PREPARING FC-CONTAINING POLYPEPTIDES WITH IMPROVED PROPERTIES
UA113626C2 (xx) 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
MX391293B (es) 2011-06-10 2025-03-21 Hanmi Science Co Ltd DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS.
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
KR101577734B1 (ko) 2011-06-17 2015-12-29 한미사이언스 주식회사 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도
PT2726508T (pt) 2011-06-28 2017-09-26 Oxford Biotherapeutics Ltd Anticorpos para adp-ribosil ciclase 2
BR112013032630B1 (pt) 2011-06-30 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Polipeptídeo heterodimerizado compreendendo região fc de igg
JP2014520869A (ja) 2011-07-18 2014-08-25 アルツ バイオロジクス アクティーゼルスカブ 長期作用性で生物学的活性が有る黄体形成ホルモン（ｌｈ）化合物
GB201112429D0 (en) 2011-07-19 2011-08-31 Glaxo Group Ltd Antigen-binding proteins with increased FcRn binding
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013036032A1 (en) 2011-09-05 2013-03-14 Hanmi Science Co., Ltd. A pharmaceutical composition for treating cancer, comprising interferon alpha conjugate
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US9006400B2 (en) 2011-09-26 2015-04-14 Novartis Ag Fibroblast growth factor-21-Fc fusion proteins
EP2762493B1 (en) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
PL2760471T3 (pl) 2011-09-30 2017-07-31 Dana-Farber Cancer Institute, Inc. Peptydy terapeutyczne
RU2014117505A (ru) 2011-09-30 2015-11-10 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула для ускорения удаления антигенов
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
WO2013067055A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Methods of blocking cancer stem cell growth
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
WO2013067060A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
DK2773671T3 (da) 2011-11-04 2021-11-15 Zymeworks Inc Udformning af stabilt heterodimert antistof med mutationer i fc-domænet
AU2012332263A1 (en) 2011-11-04 2014-05-22 Novartis Ag Low density lipoprotein-related protein 6 (LRP6) - half life extender constructs
LT2776466T (lt) 2011-11-11 2017-11-27 Ucb Biopharma Sprl Albuminą prisijungiantys antikūnai ir jų prisijungimo fragmentai
MX352738B (es) 2011-11-17 2017-12-06 Pfizer Peptidos citotoxicos y conjugados de anticuerpo-farmaco de los mismos.
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
CN104159924B (zh) 2011-12-05 2018-03-16 诺华股份有限公司 表皮生长因子受体3(her3)的抗体
JP2015500829A (ja) 2011-12-05 2015-01-08 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉに対するｈｅｒ３の抗体
EP2794657B1 (en) 2011-12-19 2017-10-11 Xoma (Us) Llc Methods for treating acne
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
EP3663314A1 (en) 2012-01-09 2020-06-10 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
WO2013106485A2 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
JP6226752B2 (ja) 2012-02-09 2017-11-08 中外製薬株式会社 抗体のＦｃ領域改変体
PL2817338T3 (pl) 2012-02-24 2017-12-29 Abbvie Stemcentrx Llc Modulatory DLL3 i sposoby zastosowania
TWI682939B (zh) 2012-02-24 2020-01-21 日商中外製藥股份有限公司 經ＦｃγＲＩＩＢ促進抗原消失之抗原結合分子
WO2013134288A1 (en) 2012-03-05 2013-09-12 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
KR101665009B1 (ko) 2012-03-09 2016-10-11 한미사이언스 주식회사 비알콜성 지방간 질환의 예방 또는 치료용 약학적 조성물
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10064951B2 (en) 2012-03-30 2018-09-04 Hanmi Science Co., Ltd. Liquid formulation of highly concentrated long-acting human growth hormone conjugate
WO2013169693A1 (en) 2012-05-09 2013-11-14 Bristol-Myers Squibb Company Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
JP6351572B2 (ja) 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR102144069B1 (ko) 2012-05-15 2020-08-13 시애틀 지네틱스, 인크. 자가-안정화 링커 접합체
JP6294311B2 (ja) * 2012-05-23 2018-03-14 ジェネンテック， インコーポレイテッド 治療薬の選択方法
WO2013180201A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014004549A2 (en) 2012-06-27 2014-01-03 Amgen Inc. Anti-mesothelin binding proteins
HRP20181595T1 (hr) 2012-07-13 2018-12-14 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 protutijela i njihova upotreba u liječenju očnih krvožilnih bolesti
EP2875046B2 (en) 2012-07-19 2025-04-30 Amgen Inc. Human btnl3 proteins, nucleic acids, and antibodies and uses thereof
AR092862A1 (es) 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
AR091902A1 (es) 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
CN104812775B (zh) 2012-07-25 2019-05-03 塞尔德克斯医疗公司 抗kit抗体及其用途
MX371442B (es) 2012-08-24 2020-01-30 Chugai Pharmaceutical Co Ltd VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
HUE036433T2 (hu) 2012-11-05 2018-07-30 Pfizer Spliceostatin analógok
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MX372833B (es) 2012-11-06 2020-06-25 Hanmi Pharm Co Tld Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina.
KR20150082548A (ko) 2012-11-07 2015-07-15 화이자 인코포레이티드 항-notch3 항체 및 항체-약물 접합체
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
ES2864326T3 (es) 2012-12-05 2021-10-13 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a EPO
JP2016505633A (ja) 2013-01-24 2016-02-25 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ＴＮＦα抗原結合性タンパク質
KR102073748B1 (ko) 2013-01-31 2020-02-05 한미약품 주식회사 재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
ES2645634T3 (es) 2013-02-12 2017-12-07 Bristol-Myers Squibb Company Métodos de replegado de proteínas a elevado pH
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
WO2014129895A1 (en) 2013-02-19 2014-08-28 Stichting Vu-Vumc Means and method for increasing the sensitivity of cancers for radiotherapy
PL2958944T3 (pl) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Koniugaty przeciwciało anty-DLL3-PBD i ich zastosowania
PT2963055T (pt) 2013-02-26 2019-07-25 Hanmi Pharm Ind Co Ltd Conugado de insulina específico ao local
PE20151409A1 (es) 2013-02-26 2015-10-07 Hanmi Pharm Ind Co Ltd Analogo de insulina novedoso y su uso
WO2014137161A1 (ko) 2013-03-05 2014-09-12 한미약품 주식회사 생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
CA2904035A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. Tnf alpha inhibitor polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same
WO2014136117A1 (en) 2013-03-06 2014-09-12 Protalix Ltd. USE OF PLANT CELLS EXPRESSING A TNFalpha POLYPEPTIDE INHIBITOR IN THERAPY
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
ES2692363T3 (es) 2013-03-14 2018-12-03 Translate Bio, Inc. Composiciones terapéuticas de ARNm y su uso para tratar enfermedades y trastornos
BR112015022790A8 (pt) 2013-03-14 2020-01-21 Univ Duke molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
AU2014233503A1 (en) 2013-03-15 2015-09-24 Abbvie Biotechnology Ltd. Anti-CD25 antibodies and their uses
CN110143999B (zh) 2013-03-15 2023-12-05 酵活英属哥伦比亚省公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
CA2904528C (en) 2013-03-15 2021-01-19 Abbvie Biotherapeutics Inc. Fc variants
EP2970908B1 (en) 2013-03-15 2019-12-25 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
JP2016515524A (ja) 2013-03-15 2016-05-30 アッヴィ バイオテクノロジー リミテッド 抗ｃｄ２５抗体およびそれらの使用
JP6505079B2 (ja) 2013-03-29 2019-04-24 アレクシオン ファーマシューティカルズ， インコーポレイテッド 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
ES2871383T3 (es) 2013-04-29 2021-10-28 Hoffmann La Roche Anticuerpos asimétricos modificados que se unen al receptor de Fc y procedimientos de uso
KR101895634B1 (ko) 2013-05-31 2018-09-05 한미약품 주식회사 변이된 힌지 영역을 포함하는 IgG4 Fc 단편
ES2891755T3 (es) 2013-06-06 2022-01-31 Pf Medicament Anticuerpos anti-C10orf54 y utilizaciones de los mismos
AU2014278833A1 (en) 2013-06-13 2016-01-07 Fast Forward Pharmaceuticals B.V. CD40 signalling inhibitor and a further compound, wherein the further compound is a bile acid, a bile acid derivative, an TGR5-receptor agonist, an FXR agonist or a combination thereof, for the treatment of chronic inflammation, and the prevention of gastrointestinal cancer or fibrosis.
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
AR096890A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
EP3022224A2 (en) 2013-07-18 2016-05-25 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
CA2918370A1 (en) 2013-07-18 2015-01-22 Fabrus, Inc. Humanized antibodies with ultralong complementarity determining regions
CA2918077A1 (en) 2013-07-25 2015-01-29 Novartis Ag Bioconjugates of synthetic apelin polypeptides
CA2918074A1 (en) 2013-07-25 2015-01-29 Novartis Ag Cyclic polypeptides for the treatment of heart failure
CA2919477A1 (en) 2013-07-31 2015-02-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
PT3041507T (pt) 2013-08-26 2021-07-26 Biontech Res And Development Inc Ácidos nucleicos que codificam anticorpos humanos para sialil-lewis
KR20160044042A (ko) 2013-08-28 2016-04-22 스템센트알엑스 인코포레이티드 부위-특이적 항체 접합 방법 및 조성물
RU2016111139A (ru) 2013-08-28 2017-10-03 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые модуляторы sez6 и способы их применения
WO2015035044A2 (en) 2013-09-04 2015-03-12 Abbvie Biotherapeutics Inc. Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
TW201605468A (zh) 2013-09-27 2016-02-16 韓美藥品股份有限公司 長效人類生長激素接合物之製劑
JP6747971B2 (ja) 2013-10-15 2020-08-26 シアトル ジェネティックス， インコーポレイテッド 改善されたリガンド−薬物コンジュゲート薬物動態のためのｐｅｇ化薬物−リンカー
EP3057605A1 (en) 2013-10-18 2016-08-24 Novartis AG Methods of treating diabetes and related disorders
WO2015069794A2 (en) 2013-11-06 2015-05-14 Stem Centrx, Inc. Novel anti-claudin antibodies and methods of use
EP3094973B1 (en) 2013-11-07 2020-07-29 Diagnodus Limited Biomarkers
RU2737882C2 (ru) 2013-11-27 2020-12-04 Займворкс Инк. Биспецифические антигенсвязывающие конструкции против her2
BR112016012358A2 (pt) 2013-12-06 2017-09-26 Dana Farber Cancer Inst Inc peptídios terapêuticos
HUE060643T2 (hu) 2013-12-19 2023-04-28 Seagen Inc Metilén-karbamát-linkerek célzott hatóanyag-konjgátumokkal közös alkalmazásra
CN105849108A (zh) 2013-12-20 2016-08-10 吉利德卡利斯托加公司 磷脂酰肌醇3-激酶抑制剂的制备方法
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
LT3087095T (lt) 2013-12-24 2019-09-10 Argenx Bvba Fcrn-antagonistai ir naudojimo būdai
PL3086815T3 (pl) 2013-12-27 2022-06-13 Zymeworks Inc. Układy łącznikowe dla koniugatów leków zawierające ugrupowanie sulfonamidowe
CA2932364A1 (en) 2014-01-15 2015-07-23 F. Hoffmann-La Roche Ag Fc-region variants with improved protein a-binding
JP6786392B2 (ja) * 2014-01-15 2020-11-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＦｃＲｎ結合特性が改変され、プロテインＡ結合特性が保持されているＦｃ領域変異体
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
KR102489475B1 (ko) 2014-01-24 2023-01-20 엔지엠 바이오파마슈티컬스, 아이엔씨. 결합 단백질 및 그의 사용 방법
MX371147B (es) 2014-01-27 2020-01-20 Pfizer Agentes citotoxicos bifuncionales.
ES2885686T3 (es) 2014-02-17 2021-12-15 Seagen Inc Conjugados anticuerpo-fármaco hidrófilos
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
CA3124243A1 (en) 2014-03-14 2015-09-17 Dana-Farber Cancer Institute, Inc. Vaccine compositions and methods for restoring nkg2d pathway function against cancers
ES2897935T3 (es) 2014-03-31 2022-03-03 Hanmi Pharm Ind Co Ltd Método para mejorar la solubilidad de proteína y péptido mediante el uso del enlace a un fragmento Fc de inmunoglobulina
AU2015240599B2 (en) 2014-04-04 2020-11-19 Bionomics, Inc. Humanized antibodies that bind LGR5
AU2015259465A1 (en) 2014-05-13 2016-11-17 Bioatla Llc Conditionally active biological proteins
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
PH12016502345B1 (en) 2014-05-28 2023-03-01 Agenus Inc Anti-gitr antibodies and methods of use thereof
AR100639A1 (es) 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
AR100695A1 (es) 2014-05-30 2016-10-26 Hanmi Pharm Ind Co Ltd Composición para el tratamiento de diabetes mellitus que comprende insulina y un agonista dual glp-1 / glucagón
KR102614642B1 (ko) 2014-06-04 2023-12-19 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체
KR20150140177A (ko) 2014-06-05 2015-12-15 한미약품 주식회사 단백질 및 펩타이드의 면역원성을 감소시키는 방법
ES2901705T3 (es) 2014-06-06 2022-03-23 Bristol Myers Squibb Co Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (GITR) y usos de los mismos
AU2015274574B2 (en) 2014-06-10 2019-10-10 Amgen Inc. Apelin polypeptides
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
CN106573955B (zh) 2014-06-23 2021-02-26 诺华股份有限公司 位点特异性蛋白质修饰
CA2953816C (en) 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
TWI675043B (zh) 2014-08-07 2019-10-21 瑞士商諾華公司 血管生成素樣４抗體及其使用方法
AP2017009776A0 (en) 2014-09-03 2017-02-28 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CA2960756C (en) 2014-09-15 2023-08-01 Amgen Inc. Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof
TWI772252B (zh) 2014-09-16 2022-08-01 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SI3221363T1 (sl) 2014-11-21 2020-09-30 Bristol-Myers Squibb Company Protitelesa proti CD73 in njihova uporaba
RS60998B1 (sr) 2014-11-21 2020-11-30 Bristol Myers Squibb Co Antitela koja sadrže modifikovane regione teškog lanca
GB201421901D0 (en) 2014-12-09 2015-01-21 Cambridge Entpr Ltd A method of rational antibody design
HUE052771T2 (hu) 2014-12-11 2021-05-28 Pf Medicament C10orf54 elleni antitestek és alkalmazásuk
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
AR103161A1 (es) 2014-12-19 2017-04-19 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina y regiones fc variantes así como métodos de uso
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
US10221248B2 (en) 2014-12-22 2019-03-05 The Rockefeller University Anti-MERTK agonistic antibodies and uses thereof
CA2971732A1 (en) 2014-12-23 2016-06-30 Bristol-Myers Squibb Company Antibodies to tigit
UA126960C2 (uk) 2014-12-30 2023-03-01 Ханмі Фарм. Ко., Лтд. Похідна глюкагону
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
WO2016123454A1 (en) 2015-01-29 2016-08-04 Board Of Trustees Of Miching State University Cryptic polypeptides and uses thereof
EP3816179A3 (en) 2015-02-05 2021-08-04 Chugai Seiyaku Kabushiki Kaisha Fc region variant comprising a modified fcrn-binding domain
WO2016133372A2 (ko) 2015-02-17 2016-08-25 한미약품 주식회사 지속형 인슐린 또는 이의 아날로그 결합체
ES2937020T3 (es) 2015-03-03 2023-03-23 Kymab Ltd Anticuerpos, usos y métodos
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
SG11201706991YA (en) 2015-03-20 2017-10-30 Pfizer Bifunctional cytotoxic agents containing the cti pharmacophore
SG10202008304TA (en) 2015-05-29 2020-10-29 Bristol Myers Squibb Co Antibodies against ox40 and uses thereof
EA201792561A1 (ru) 2015-06-05 2018-04-30 Новартис Аг Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN108025041A (zh) 2015-06-30 2018-05-11 韩美药品株式会社 胰高血糖素衍生物和包含其长效缀合物的组合物
CN115043944B (zh) 2015-08-03 2024-08-20 诺华股份有限公司 治疗fgf21相关病症的方法
CN108289928B (zh) 2015-08-06 2024-09-17 哈佛大学校长及研究员协会 改进的微生物-结合分子和其用途
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
WO2017040790A1 (en) 2015-09-01 2017-03-09 Agenus Inc. Anti-pd-1 antibodies and methods of use thereof
PT3347377T (pt) 2015-09-09 2021-04-30 Novartis Ag Anticorpos que se ligam à linfopoietina do estroma tímico (tslp) e métodos de utilização dos anticorpos
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
WO2017049004A1 (en) 2015-09-15 2017-03-23 Amgen Inc. Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
US11389508B2 (en) 2015-09-24 2022-07-19 Hanmi Pharm. Co., Ltd. Protein complex by use of a specific site of an immunoglobulin fragment for linkage
AU2016332900C1 (en) 2015-09-29 2024-07-04 Amgen Inc. ASGR inhibitors
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
JP2018529729A (ja) 2015-10-01 2018-10-11 アムジエン・インコーポレーテツド 胆汁酸障害の処置
CA3002573A1 (en) 2015-11-03 2017-05-11 Ambrx, Inc. Anti-cd3 antibodies and their uses
CN107043406B (zh) 2015-11-03 2021-08-17 财团法人工业技术研究院 化合物、连接子-药物、及配体-药物耦合体
BR112018010172A2 (pt) 2015-11-19 2018-11-21 Bristol Myers Squibb Co anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos
US10195209B2 (en) 2015-11-30 2019-02-05 Abbvie Inc. Anti-huLRRC15 antibody drug conjugates and methods for their use
EP3383909B1 (en) 2015-11-30 2020-06-17 AbbVie Inc. Anti-human lrrc15 antibody drug conjugates and methods for their use
AU2016364889B2 (en) 2015-12-02 2024-01-04 Agenus Inc. Antibodies and methods of use thereof
WO2017096262A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
EP3383891A1 (en) 2015-12-04 2018-10-10 Novartis AG Antibody cytokine engrafted compositions and methods of use for immunoregulation
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
DK3398961T3 (da) 2015-12-31 2022-08-22 Hanmi Pharm Ind Co Ltd Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor
MA43859A (fr) 2016-01-11 2018-11-21 Novartis Ag Anticorps monoclonaux humainisés immunostimulants dirigés contre l'interleukine -2 humaine, et leurs protéines de fusion
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
AR107483A1 (es) 2016-01-29 2018-05-02 Hanmi Pharm Ind Co Ltd Conjugado de enzimas terapéuticas
US10723727B2 (en) 2016-02-01 2020-07-28 Pfizer Inc. Tubulysin analogs and methods for their preparation
KR20230038311A (ko) 2016-03-04 2023-03-17 브리스톨-마이어스 스큅 컴퍼니 항-cd73 항체와의 조합 요법
US10894835B2 (en) 2016-03-04 2021-01-19 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
CN119264413A (zh) 2016-03-07 2025-01-07 韩美药品株式会社 聚乙二醇衍生物及其用途
MX2018011219A (es) 2016-03-16 2019-01-10 Merrimack Pharmaceuticals Inc Trail diseñado por ingenieria para terapia de cancer.
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
EP3433278A4 (en) 2016-03-25 2019-11-06 Seattle Genetics, Inc. METHOD FOR THE PRODUCTION OF PEGYLATED ACTIVE LINKERS AND INTERMEDIATE PRODUCTS THEREOF
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
WO2017180813A1 (en) 2016-04-15 2017-10-19 Macrogenics, Inc. Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
US10934359B2 (en) 2016-04-21 2021-03-02 Abbvie Stemcentrx Llc Anti-BMPR1B antibodies and methods of use
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
KR102366813B1 (ko) 2016-05-27 2022-02-24 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
JP7037506B2 (ja) * 2016-05-27 2022-03-16 アルター・バイオサイエンス・コーポレーション Ｃｄ３結合ドメインを有する多量体ｉｌ－１５系分子の構築及び特性評価
MX2018014560A (es) 2016-05-27 2019-08-12 Alexion Pharma Inc Metodos para el tratamiento de la miastenia gravis generalizada refractaria.
JP7148504B2 (ja) 2016-06-08 2022-10-05 ゼンコー，インコーポレイティド ＣＤ３２Ｂに交差結合した抗ＣＤ１９抗体を用いたＩｇＧ４関連疾患の治療
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
WO2017218691A1 (en) 2016-06-16 2017-12-21 The Board Of Trustees Of The Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd81
KR20230129583A (ko) 2016-06-21 2023-09-08 테네오바이오, 인코포레이티드 Cd3 결합 항체
TWI757305B (zh) 2016-06-29 2022-03-11 南韓商韓美藥品股份有限公司 升糖素衍生物、其接合物、及包含其之組成物、及其醫療用途
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
AU2017297506A1 (en) 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
EP3494134B1 (en) 2016-08-02 2025-12-10 Visterra, Inc. Engineered polypeptides and uses thereof
WO2018025168A1 (en) 2016-08-03 2018-02-08 Pfizer Inc. Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
CN116251182A (zh) 2016-08-05 2023-06-13 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
CN109562152B (zh) 2016-08-09 2024-04-02 西雅图基因公司 含有具有改善的生理化学性质的自稳定性接头的药物缀合物
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP4050034B1 (en) 2016-09-14 2024-05-08 TeneoOne, Inc. Cd3 binding antibodies
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
EP3517544B1 (en) 2016-09-23 2025-01-08 Hanmi Pharm. Co., Ltd. Insulin analog having reduced binding force to insulin receptor, and use thereof
CA3037380A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
KR20190074292A (ko) 2016-10-18 2019-06-27 시애틀 지네틱스, 인크. 니코틴아미드 아데닌 디뉴클레오티드의 구제 경로 저해제의 표적화된 전달
ES2848206T3 (es) 2016-10-19 2021-08-05 Alexion Pharma Inc Un método de cuantificar C5 sin unir en una muestra
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES, AND PROCESSES FOR USE
MX2019005552A (es) 2016-11-14 2019-08-12 Amgen Inc Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
CN110662770A (zh) 2016-11-23 2020-01-07 比奥维拉迪维治疗股份有限公司 结合凝血因子ix和凝血因子x的双特异性抗体
CN110291103A (zh) 2016-12-05 2019-09-27 韩美药品株式会社 具有弱化的免疫应答的缀合物
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
IL307242A (en) 2016-12-07 2023-11-01 Agenus Inc Anti-CTLA-4 antibodies and methods of using them
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
US20190352335A1 (en) 2016-12-19 2019-11-21 Hanmi Pharm. Co., Ltd. Brain targeting long-acting protein conjugate
KR102633423B1 (ko) 2016-12-21 2024-02-06 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
IL308980A (en) 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
EP3558370A2 (en) 2016-12-23 2019-10-30 Novartis AG Methods of treatment with anti-factor xi/xia antibodies
WO2018129384A1 (en) 2017-01-06 2018-07-12 Avidity Biosciences Llc Nucleic acid-polypeptide compositions and methods of inducing exon skipping
TW201833140A (zh) 2017-01-09 2018-09-16 美商莫瑞麥克製藥公司 抗fgfr抗體及使用方法
SG11201906414VA (en) 2017-01-24 2019-08-27 Pfizer Calicheamicin derivatives and antibody drug conjugates thereof
US20200230250A1 (en) 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
JP7121024B2 (ja) 2017-02-07 2022-08-17 ハンミ ファーマシューティカルズ カンパニー リミテッド 非ペプチド性重合体リンカー化合物、そのリンカー化合物を含む結合体、及びそれらの製造方法
FI3580237T3 (fi) 2017-02-08 2025-07-21 Novartis Ag FGF21-mimeettivasta-aineita ja niiden käyttöjä
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
CA3216726C (en) 2017-03-06 2025-08-05 Altor Bioscience Corp Il-15-based fusions to il-12 and il-18
KR101941975B1 (ko) 2017-03-17 2019-01-25 고려대학교 산학협력단 Atpif1을 함유하는 당뇨 치료용 약학조성물
EP3604328A4 (en) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. INSULIN ANALOGUE COMPLEX WITH REDUCED AFFINITY FOR THE INSULIN RECEPTOR AND USE OF IT
CN110430901B (zh) 2017-03-24 2024-08-16 西雅图基因公司 制备葡糖苷酸药物-接头及其中间体的方法
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
EP3606560A2 (en) 2017-04-05 2020-02-12 Novo Nordisk A/S Oligomer extended insulin-fc conjugates
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11634495B2 (en) 2017-04-07 2023-04-25 Miltenyi Biotec B.V. & Co. KG Methods of activating CD32b/c comprising administering an antibody that binds BDCA-2 (CD303)
WO2018191502A2 (en) 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US11643473B2 (en) 2017-04-24 2023-05-09 Alexion Pharmaceuticals, Inc. Antibody immune cell inhibitor fusion proteins
CN110799217A (zh) 2017-04-27 2020-02-14 西雅图基因公司 季铵化烟酰胺腺嘌呤二核苷酸补救途径抑制剂缀合物
RS64576B1 (sr) 2017-05-01 2023-10-31 Agenus Inc Anti-tigit antitela i postupci njihove primene
EP3625251A1 (en) 2017-05-15 2020-03-25 University Of Rochester Broadly neutralizing anti-influenza monoclonal antibody and uses thereof
JP2020520665A (ja) 2017-05-24 2020-07-16 ノバルティス アーゲー 抗体−サイトカイングラフト化タンパク質及び癌の治療における使用方法
EP3630162A1 (en) 2017-05-24 2020-04-08 Novartis AG Antibody-cytokine engrafted proteins and methods of use
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
IL270596B1 (en) 2017-05-25 2025-09-01 Bristol Myers Squibb Co Antibodies comprising modified heavy constant region for use in treating cancer
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
CA3067584A1 (en) 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2019009684A2 (ko) 2017-07-07 2019-01-10 한미약품 주식회사 신규 치료학적 효소 융합단백질 및 이의 용도
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
BR112020001703B1 (pt) 2017-07-27 2024-01-02 Alexion Pharmaceuticals, Inc Solução aquosa estável compreendendo um anticorpo anti-c5, método para produção desta solução, uso da mesma para tratar uma condição associada ao complemento e kit terapêutico compreendendo a mesma
PE20200797A1 (es) 2017-08-25 2020-08-10 Five Prime Therapeutics Inc Anticuerpos que se unen especificamente a b7-h4 humana
WO2019046313A1 (en) 2017-08-28 2019-03-07 Altor Bioscience Llc IL-15 BASED FUSIONS WITH IL-7 AND IL-21
JP2020533362A (ja) 2017-09-13 2020-11-19 テネオバイオ， インコーポレイテッド エクト酵素に結合する重鎖抗体
AR113258A1 (es) 2017-09-28 2020-03-11 Hanmi Pharm Ind Co Ltd Conjugados persistentes de derivados del péptido 2 similar al glucagón (glp-2)
KR20190036956A (ko) 2017-09-28 2019-04-05 한미약품 주식회사 지속형 단쇄 인슐린 아날로그 및 이의 결합체
KR20190038456A (ko) 2017-09-29 2019-04-08 한미약품 주식회사 효력이 향상된 지속성 단백질 결합체
EP3689942B1 (en) 2017-09-29 2024-06-19 Hanmi Pharm. Co., Ltd. Protein complex comprising non-peptidyl polymer-coupled fatty acid derivative compound as linker and preparation method therefor
KR102822647B1 (ko) 2017-10-04 2025-06-19 어비디티 바이오사이언시스 인크. 핵산-폴리펩티드 조성물 및 그의 용도
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN111630069B (zh) 2017-10-13 2024-05-31 勃林格殷格翰国际有限公司 针对Thomsen-nouvelle(Tn)抗原的人抗体
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
CA3080187A1 (en) 2017-10-26 2019-05-02 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) and atypical hemolytic uremic syndrome (ahus)
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
JP7731196B2 (ja) 2017-11-14 2025-08-29 中外製薬株式会社 抗Ｃ１ｓ抗体および使用方法
IL319835A (en) 2017-12-06 2025-05-01 Avidity Biosciences Inc Compositions and methods for treating muscular dystrophy and myotonic dystrophy
AU2018380979B2 (en) 2017-12-08 2023-07-20 argenx BV Use of FcRn antagonists for treatment of generalized myasthenia gravis
ES2983433T3 (es) 2017-12-22 2024-10-23 Novartis Ag Tratamiento de trastornos metabólicos con variantes de FGF21
JP7403455B2 (ja) 2017-12-22 2023-12-22 ハンミ ファーマシューティカル カンパニー リミテッド 新規な構造を有する治療学的酵素融合タンパク質及びその用途
EP3728319A1 (en) 2017-12-22 2020-10-28 TeneoBio, Inc. Heavy chain antibodies binding to cd22
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
US11306149B2 (en) 2017-12-27 2022-04-19 Bristol-Myers Squibb Company Anti-CD40 antibodies and uses thereof
KR20200104364A (ko) * 2017-12-27 2020-09-03 테네오바이오, 인코포레이티드 Cd3-델타/엡실론 이형이량체 특이적 항체
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
AR114080A1 (es) 2018-01-12 2020-07-22 Amgen Inc Anticuerpos pac1 y sus usos
WO2019164987A1 (en) 2018-02-20 2019-08-29 Seattle Genetics, Inc. Hydrophobic auristatin f compounds and conjugates thereof
WO2019165077A1 (en) 2018-02-21 2019-08-29 Five Prime Therapeutics, Inc. B7-h4 antibody formulations
CN111787951B (zh) * 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
KR20200144094A (ko) 2018-03-02 2020-12-28 파이브 프라임 테라퓨틱스, 인크. B7-h4 항체 및 이의 사용 방법
EP3768715A1 (en) 2018-03-23 2021-01-27 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
EP3773657A4 (en) 2018-03-26 2021-12-08 Altor Bioscience LLC ANTI-PDL1, IL-15 AND TGF BETA RECEPTOR COMBINATION MOLECULES
CN110305210B (zh) 2018-03-27 2023-02-28 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
WO2019184909A1 (zh) 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途
US20210046189A1 (en) 2018-03-30 2021-02-18 HANMl PHARM. CO., LTD. Long-acting protein conjugates for brain targeting, a preparation method thereof, and a composition comprising the same
AU2019248547B2 (en) 2018-04-02 2025-07-17 Bristol-Myers Squibb Company Anti-TREM-1 antibodies and uses thereof
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019209078A1 (ko) 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP3787678A1 (en) 2018-05-03 2021-03-10 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
EP3790904A1 (en) 2018-05-08 2021-03-17 Amgen Inc. Bispecific antibodies with cleavable c-terminal charge-paired tags
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3802593B1 (en) 2018-05-31 2024-09-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
WO2019236345A1 (en) 2018-06-04 2019-12-12 Alexion Pharmaceuticals, Inc. DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (aHUS) IN PEDIATRIC PATIENTS
TW202519270A (zh) 2018-06-07 2025-05-16 美商思進公司 喜樹鹼結合物
CA3101462A1 (en) 2018-06-08 2019-12-12 Argenx Bvba Compositions and methods for treating immune thrombocytopenia
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
MX2020013525A (es) 2018-06-15 2021-02-26 Proclara Biosciences Inc Motivo de interaccion amiloide general.
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
US12312394B2 (en) 2018-06-28 2025-05-27 Alexion Pharmaceuticals, Inc. Methods of producing anti-C5 antibodies
JP7439046B2 (ja) 2018-07-20 2024-02-27 テネオツー・インコーポレイテッド Ｃｄ１９に結合する重鎖抗体
CA3106418A1 (en) 2018-07-20 2020-01-23 Pierre Fabre Medicament Receptor for vista
CA3107159A1 (en) 2018-07-24 2020-01-30 Good T Cells, Inc. Composition for preventing or treating immune-related diseases
AU2019318031B2 (en) 2018-08-10 2025-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-CD137 antigen-binding molecule and utilization thereof
US12350316B2 (en) 2018-08-16 2025-07-08 Nantbio, Inc. IL7-IL 15 TxM compositions and methods
CA3113057A1 (en) 2018-09-21 2020-03-26 Teneobio, Inc. Methods for purifying heterodimeric, multispecific antibodies
CN110964116A (zh) 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
KR20210086619A (ko) 2018-09-27 2021-07-08 셀진 코포레이션 SIRPα 결합 단백질 및 이의 사용 방법
KR20210070300A (ko) 2018-10-03 2021-06-14 스태튼 바이오테크놀로지 비.브이. 사람 및 시노몰구스 ApoC3에 대해 특이적인 항체 및 이의 사용 방법
CN113164559A (zh) 2018-10-04 2021-07-23 韩美药品株式会社 胰高血糖素和包括胰高血糖素的组合产品的治疗用途
CN112839681A (zh) 2018-10-10 2021-05-25 诺和诺德股份有限公司 寡聚体延伸的胰岛素-Fc缀合物及其医学用途
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
WO2020087065A1 (en) 2018-10-26 2020-04-30 Teneobio, Inc. Heavy chain antibodies binding to cd38
WO2020092549A1 (en) 2018-10-30 2020-05-07 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
WO2020112781A1 (en) 2018-11-28 2020-06-04 Bristol-Myers Squibb Company Antibodies comprising modified heavy constant regions
US20220064248A1 (en) 2018-12-21 2022-03-03 HANMl PHARM. CO., LTD Pharmaceutical composition including insulin and glucagon
IL319265A (en) 2018-12-21 2025-04-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and their uses
WO2020130749A1 (ko) 2018-12-21 2020-06-25 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
PH12021551783A1 (en) 2019-01-22 2022-05-30 Bristol Myers Squibb Co Antibodies against il-7r alpha subunit and uses thereof
WO2020176497A1 (en) 2019-02-26 2020-09-03 Rgenix, Inc. High-affinity anti-mertk antibodies and uses thereof
KR20210149076A (ko) 2019-04-05 2021-12-08 테네오바이오, 인코포레이티드 Psma에 결합하는 중쇄 항체
KR102524577B1 (ko) 2019-04-22 2023-04-21 전남대학교산학협력단 플라젤린 융합 단백질 및 이의 용도
CA3138550A1 (en) 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use
IL287938B2 (en) 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
KR20220016865A9 (ko) 2019-05-15 2022-02-21 추가이 세이야쿠 가부시키가이샤 항원 결합 분자, 약학 조성물, 및 방법
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN120204385A (zh) 2019-05-24 2025-06-27 赛诺菲 治疗系统性硬化症的方法
MX2021014534A (es) 2019-05-30 2022-02-11 Amgen Inc Modificación por ingeniería genética de la región bisagra para impulsar la dimerización de anticuerpos.
CA3142337A1 (en) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Una amidites and uses thereof
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
WO2020245420A1 (en) 2019-06-07 2020-12-10 Argenx Bvba PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
BR112021024956A2 (pt) 2019-06-14 2022-01-25 Teneobio Inc Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
MX2021015791A (es) 2019-06-28 2022-04-01 Amgen Inc Proteínas de unión al antígeno biespecificas anti-receptor de cgrp/anti-receptor pac1.
IL291681B2 (en) 2019-06-28 2024-01-01 Hanmi Pharm Ind Co Ltd Therapeutic use of trigonal glucagon/glp-1/gip receptor agonist or conjugate thereof for liver disease
CN114174536A (zh) 2019-07-15 2022-03-11 百时美施贵宝公司 抗trem-1抗体及其用途
EP3999541A1 (en) 2019-07-15 2022-05-25 Bristol-Myers Squibb Company Antibodies against human trem-1 and uses thereof
KR102334315B1 (ko) 2019-07-18 2021-12-06 한미약품 주식회사 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
US20230374130A1 (en) 2019-07-30 2023-11-23 Qlsf Biotherapeutics, Inc. Bispecific anti lrrc15 and cd3epsilon antibodies
JP7691138B2 (ja) 2019-08-12 2025-06-11 アプティーボ リサーチ アンド デベロップメント エルエルシー ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体
WO2021042019A1 (en) 2019-08-30 2021-03-04 Agenus Inc. Anti-cd96 antibodies and methods of use thereof
TW202122116A (zh) 2019-09-05 2021-06-16 西班牙商瑪製藥股份有限公司 藥物抗體偶聯物
EP4031578A1 (en) 2019-09-18 2022-07-27 Novartis AG Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
MX2022003268A (es) 2019-09-19 2022-06-02 Seagen Inc Liberacion selectiva de farmaco a partir de conjugados internalizados de compuestos biologicamente activos.
US20230000950A1 (en) 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
JP2022550851A (ja) 2019-10-04 2022-12-05 シージェン インコーポレイテッド カンプトテシンペプチドコンジュゲート
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CA3158893A1 (en) 2019-10-24 2021-04-29 Minotaur Therapeutics, Inc. Chimeric cytokine modified antibodies and methods of use thereof
AU2020380379A1 (en) 2019-11-08 2022-05-26 Amgen Inc. Engineering charge pair mutations for pairing of hetero-IgG molecules
WO2021102049A1 (en) 2019-11-19 2021-05-27 Amgen Inc. Novel multispecific antibody format
US20230048046A1 (en) 2019-12-13 2023-02-16 Cugene Inc Novel interleukin-15 (il-15) fusion proteins and uses thereof
JP2023507120A (ja) 2019-12-18 2023-02-21 テネオフォー， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
GB201919061D0 (en) 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibody
UY38995A (es) 2019-12-20 2021-06-30 Amgen Inc Constructos de anticuerpo multiespecíficos agonistas de cd40 dirigidos a mesotelina para el tratamiento de tumores sólidos
KR20210082120A (ko) 2019-12-24 2021-07-02 한미약품 주식회사 Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
PH12022551646A1 (en) 2020-01-08 2024-02-12 argenx BV Methods for treating pemphigus disorders
CN115209913A (zh) 2020-01-13 2022-10-18 韩美药品株式会社 对胰高血糖素/glp-1/gip受体均具有活性的三重激动剂的长效缀合物对肺病的治疗用途
WO2021173773A1 (en) 2020-02-25 2021-09-02 Mediboston, Inc. Camptothecin derivatives and conjugates thereof
IL296387B2 (en) 2020-03-19 2024-08-01 Avidity Biosciences Inc Preparations and methods for the treatment of facial, back and arm muscle atrophy
US11365239B2 (en) 2020-03-20 2022-06-21 Tsb Therapeutics (Beijing) Co., Ltd. Anti-SARS-COV-2 antibodies and uses thereof
RS65199B1 (sr) 2020-03-26 2024-03-29 Univ Vanderbilt Humana monoklonska antitela na teški akutni respiratorni sindrom koronavirus 2 (sars-cov-2)
MX2022011880A (es) 2020-03-27 2022-10-20 Avidity Biosciences Inc Composiciones y metodos para tratar distrofia muscular.
WO2021195574A1 (en) * 2020-03-27 2021-09-30 Alnylam Pharmaceuticals, Inc. Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
KR20210121585A (ko) 2020-03-30 2021-10-08 한국세라믹기술원 반응성 및 안정성 그리고 항체회수가 향상된 z-도메인 및 칼시퀘스트린 융합단백질 및 이를 이용한 항체의 분리 및 정제 방법
US20230107644A1 (en) 2020-04-01 2023-04-06 University Of Rochester Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
CA3173353A1 (en) 2020-04-03 2021-10-07 Jin Bong Lee Pharmaceutical composition for preventing or treating mucositis induced by radiotherapy, chemotherapy, or combination thereof, comprising glp-2 derivatives or long-acting conjugate of same
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
WO2021215801A1 (ko) 2020-04-20 2021-10-28 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
US11242382B2 (en) 2020-04-20 2022-02-08 Genzyme Corporation Humanized anti-complement factor Bb antibodies
CA3175426A1 (en) 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
JP2023523480A (ja) 2020-04-28 2023-06-06 ザ ロックフェラー ユニバーシティー 中和抗ｓａｒｓ－ｃｏｖ－２抗体およびその使用方法
EP4142791A1 (en) 2020-04-29 2023-03-08 TeneoOne, Inc. Methods of treating multiple myeloma
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
IL297644A (en) 2020-04-29 2022-12-01 Teneobio Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
IL297437A (en) 2020-05-13 2022-12-01 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US20210355196A1 (en) 2020-05-17 2021-11-18 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of selecting and using the same
US20230285583A1 (en) 2020-05-22 2023-09-14 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon, glp-1, and gip trigonal agonist
US20230192800A1 (en) 2020-05-22 2023-06-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glucagon derivative
WO2021235915A1 (ko) 2020-05-22 2021-11-25 한미약품 주식회사 액상 제제
US20230285584A1 (en) 2020-05-22 2023-09-14 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2
WO2021263167A2 (en) 2020-06-26 2021-12-30 Amgen Inc. Il-10 muteins and fusion proteins thereof
PE20230464A1 (es) 2020-06-30 2023-03-14 Teneobio Inc Union de anticuerpos multiespecificos a bcma
BR112023000515A2 (pt) 2020-07-15 2023-03-21 Hanmi Pharm Ind Co Ltd Composição farmacêutica e seu uso
WO2022015710A1 (en) 2020-07-17 2022-01-20 Spectrum Pharmaceuticals, Inc. Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
MX2023000699A (es) 2020-07-17 2023-04-18 Hanmi Pharmaceutical Co Ltd Uso terapéutico de combinación que comprende un conjugado de acción prolongada triple agonista o agonista triple.
CN117487026A (zh) 2020-07-24 2024-02-02 江苏晟斯生物制药有限公司 胰岛素-Fc融合蛋白及其应用
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
CN116724236A (zh) 2020-08-06 2023-09-08 美国比奥维拉迪维股份有限公司 患有补体介导的疾病的受试者中的炎性细胞因子和疲劳
EP4192860A1 (en) 2020-08-10 2023-06-14 AstraZeneca UK Limited Sars-cov-2 antibodies for treatment and prevention of covid-19
KR20220021895A (ko) 2020-08-14 2022-02-22 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
CA3187742A1 (en) 2020-08-14 2022-02-17 Seungjae Baek Pharmaceutical composition comprising long-acting conjugate of triple glucagon/glp-1/gip receptor agonist
CA3191710A1 (en) 2020-08-20 2022-02-24 Amgen Inc. Antigen binding proteins with non-canonical disulfide in fab region
WO2022065899A1 (ko) 2020-09-25 2022-03-31 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
US20230355789A1 (en) 2020-09-25 2023-11-09 Hanmi Pharm. Co., Ltd. Therapeutic use, for neurodegenerative diseases, of triple agonist having activity with respect to all of glucagon, glp-1, and gip receptors, or conjugate thereof
KR20220041765A (ko) 2020-09-25 2022-04-01 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
WO2022076474A2 (en) 2020-10-07 2022-04-14 Amgen Inc. Rational selection of building blocks for the assembly of multispecific antibodies
WO2022080985A1 (ko) 2020-10-16 2022-04-21 한미약품 주식회사 Gip 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
US20230381281A1 (en) 2020-10-16 2023-11-30 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising glucagon/glp-1/gip triple agonist or long-acting conjugate thereof for preventing or treating lupus-related diseases
WO2022080987A1 (ko) 2020-10-16 2022-04-21 한미약품 주식회사 글루카곤/glp-1/gip 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
CN116419765A (zh) 2020-10-16 2023-07-11 韩美药品株式会社 Glp-1/gip双重激动剂、其长效缀合物，以及包括其的药物组合物
KR20220050818A (ko) 2020-10-16 2022-04-25 한미약품 주식회사 Gip 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
JP2023546384A (ja) 2020-10-16 2023-11-02 ハンミ ファーマシューティカル カンパニー リミテッド グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の呼吸器感染疾患の後遺症の治療用途
JP2023545447A (ja) 2020-10-16 2023-10-30 キューエルエスエフ バイオセラピューティクス， インコーポレイテッド Ｐｄ－ｌ１に結合する多重特異性結合化合物
US11919945B2 (en) 2020-11-04 2024-03-05 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag Cd19 binding molecules and uses thereof
TW202233251A (zh) 2020-11-09 2022-09-01 日商武田藥品工業股份有限公司 抗體藥物綴合物
CA3200603A1 (en) 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
CA3196264A1 (en) 2020-11-13 2022-05-19 Jin Young Kim Use of therapeutic enzyme fusion protein in prevention and treatment of neuropathy caused by or accompanied by farbry disease
JP2023549323A (ja) 2020-11-13 2023-11-24 ハンミ ファーマシューティカル カンパニー リミテッド 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
CA3200314A1 (en) 2020-12-01 2022-06-09 Peter Pavlik Tumor-associated antigens and cd-3 binding proteins, related compositions, and methods
PE20231953A1 (es) 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
WO2022131889A1 (ko) 2020-12-16 2022-06-23 주식회사 굳티셀 Taci 단백질의 용도
US20230382974A1 (en) 2020-12-24 2023-11-30 Hanmi Pharm. Co., Ltd. Novel triple agonist having activities on all of glucagon, glp-1, and gip receptors and use thereof
EP4302776A4 (en) 2020-12-24 2024-11-27 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMBINING AN INSULINOTROPIC PEPTIDE AND GLP-2, FOR THE PREVENTION OR TREATMENT OF SHORT BOWEL SYNDROME
JP2024502832A (ja) 2020-12-31 2024-01-23 アラマー バイオサイエンシーズ， インコーポレイテッド 高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
EP4271816A4 (en) 2020-12-31 2025-04-02 Dyne Therapeutics, Inc. MUSCLE TARGETING COMPLEXES AND RELATED USES FOR THE TREATMENT OF MYOTONIC DYSTROPHY
US12060411B2 (en) 2021-01-15 2024-08-13 The Rockefeller University Neutralizing anti-SARS-CoV-2 antibodies
JP2024505943A (ja) 2021-01-29 2024-02-08 ハンミ ファーマシューティカルズ カンパニー リミテッド Ｇｉｐ誘導体、またはその持続型結合体を含む肺疾患の予防用または治療用の薬学的組成物
CA3211138A1 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
KR20230150825A (ko) 2021-02-26 2023-10-31 테네오바이오, 인코포레이티드 항-muc1-c 항체 및 car-t 구조
KR20230158005A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
KR20230158006A (ko) 2021-03-18 2023-11-17 씨젠 인크. 생물학적 활성 화합물의 내재화된 접합체로부터의 선택적 약물 방출
IL304365B2 (en) 2021-03-31 2025-04-01 Hanmi Pharmaceutical Co Ltd A novel conjugate of an IL2 immunostimulatory analog and method of preparation thereof
WO2022212645A1 (en) 2021-03-31 2022-10-06 Bioverativ Usa Inc. Reducing surgery-associated hemolysis in cold agglutinin disease patients
JP2024514530A (ja) 2021-04-02 2024-04-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 切断型ｃｄｃｐ１に対する抗体およびその使用
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
KR20230166090A (ko) 2021-04-06 2023-12-06 테네오바이오, 인코포레이티드 항-cd19 항체 및 car-t 구조체
KR20220140443A (ko) 2021-04-09 2022-10-18 한미약품 주식회사 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
IL306045A (en) 2021-04-16 2023-11-01 Teneobio Inc Anti-cd20 antibodies and car-t structures
MX2023012324A (es) 2021-04-20 2023-10-30 Amgen Inc Distribucion de carga equilibrada en una direccion electrostatica del emparejamiento de cadenas en el conjunto de moleculas de igg multiespecificas y monovalentes.
CN118251420A (zh) 2021-04-28 2024-06-25 米诺陶治疗公司 人源化嵌合牛抗体和使用方法
EP4334343A2 (en) 2021-05-06 2024-03-13 The Rockefeller University Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
IL309349A (en) 2021-06-14 2024-02-01 argenx BV Antibodies against interleukin 9 and methods of using them
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
JP2024527514A (ja) 2021-06-25 2024-07-25 アムジエン・インコーポレーテツド Ｔｒｅｍ－１抗原結合タンパク質での循環器疾患の治療
KR20230004135A (ko) 2021-06-30 2023-01-06 한미약품 주식회사 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
AR126970A1 (es) 2021-09-02 2023-12-06 Djs Antibodies Ltd Polipétidos
KR20240055874A (ko) 2021-09-16 2024-04-29 어비디티 바이오사이언시스 인크. 안면견갑상완 근이영양증을 치료하는 조성물 및 방법
EP4408478A1 (en) 2021-09-30 2024-08-07 Seagen Inc. B7-h4 antibody-drug conjugates for the treatment of cancer
MX2024004550A (es) 2021-10-14 2024-04-29 Teneobio Inc Proteinas de union a la mesotelina y usos de las mismas.
TW202342095A (zh) 2021-11-05 2023-11-01 英商阿斯特捷利康英國股份有限公司 用於治療和預防ｃｏｖｉｄ—１９之組成物
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
KR20230095665A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 약물 및 이의 용도
KR20230095666A (ko) 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도
UY40097A (es) 2022-01-07 2023-07-14 Johnson & Johnson Entpr Innovation Inc Materiales y métodos de proteínas de unión a il-1b
US20250333485A1 (en) 2022-01-27 2025-10-30 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
TW202342510A (zh) 2022-02-18 2023-11-01 英商Ｒｑ生物科技有限公司 抗體
US20250197448A1 (en) 2022-03-11 2025-06-19 University Of Rochester Cyclopeptibodies and uses thereof
CN119278055A (zh) 2022-03-17 2025-01-07 思进公司 喜树碱缀合物
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
US20250276044A1 (en) 2022-04-18 2025-09-04 Hanmi Pharm. Co., Ltd. COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
KR20250007588A (ko) 2022-04-26 2025-01-14 노파르티스 아게 Il-13 및 il-18을 표적화하는 다중특이적 항체
AU2023262192A1 (en) 2022-04-29 2024-12-05 Astrazeneca Uk Limited Sars-cov-2 antibodies and methods of using the same
CA3258000A1 (en) 2022-06-15 2023-12-21 argenx BV FCRN/ANTIGEN BINDING MOLECULES AND METHODS OF USE
EP4539881A1 (en) 2022-06-15 2025-04-23 Bioverativ USA Inc. Anti-complement c1s antibody formulation
CN119730882A (zh) 2022-06-24 2025-03-28 美国比奥维拉迪维股份有限公司 用于治疗补体介导的疾病的方法
EP4547710A1 (en) 2022-07-01 2025-05-07 ALK-Abelló A/S Displacers of ige-fceri
CN119948051A (zh) 2022-07-15 2025-05-06 詹森生物科技公司 用于改善抗原结合可变区的生物工程化配对的材料和方法
AU2023313117A1 (en) 2022-07-27 2025-02-13 Mediboston Limited Auristatin derivatives and conjugates thereof
WO2024026358A1 (en) 2022-07-27 2024-02-01 Teneobio, Inc. Mesothelin binding proteins and uses thereof
EP4561636A1 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
KR20250058783A (ko) 2022-07-29 2025-04-30 리제너론 파마슈티칼스 인코포레이티드 트랜스페린 수용체 1로 재표적화된 바이러스 입자
JP2025525791A (ja) 2022-07-29 2025-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＴｆＲ：ペイロード融合体及びそれを使用する方法
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
WO2024036139A2 (en) 2022-08-09 2024-02-15 Qlsf Biotherapeutics, Inc. Antibodies binding to clec12a
EP4584299A2 (en) 2022-09-07 2025-07-16 Quantitative Biosciences, Inc. Fentanyl-specific single variable-domain antibodies and use in a continuous agglutination assay
JP2025535871A (ja) 2022-09-26 2025-10-30 ウォーターストーン ファーマシューティカルズ（ウーハン）カンパニー，リミティド Ｆｃ－長鎖脂肪酸鎖を含む超長作用型プラットフォーム
AU2023356984A1 (en) 2022-10-05 2025-03-20 Amgen Inc. Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
AU2023371614A1 (en) 2022-11-04 2025-05-15 Regeneron Pharmaceuticals, Inc. Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
US20240158515A1 (en) 2022-11-14 2024-05-16 Regeneron Pharmaceuticals, Inc. Anti-fgfr3 antibodies and antigen-binding fragments and methods of use thereof
CN120500498A (zh) 2022-11-14 2025-08-15 瑞泽恩制药公司 用于成纤维细胞生长因子受体3介导的至星形胶质细胞的递送的组合物及方法
EP4634227A1 (en) 2022-12-13 2025-10-22 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
KR20240102886A (ko) 2022-12-23 2024-07-03 한미약품 주식회사 면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제
IL321556A (en) 2022-12-23 2025-08-01 Hanmi Pharmaceutical Co Ltd A pharmaceutical preparation for the prevention or treatment of graft-versus-host disease containing a GLP-2 derivative or a conjugate thereof with long-term activity
WO2024150074A2 (en) 2023-01-13 2024-07-18 Takeda Pharmaceutical Company Limited Coronavirus antibodies and therapeutic uses thereof
WO2024178056A1 (en) 2023-02-21 2024-08-29 Teneobio, Inc. C-kit binding proteins, chimeric antigen receptors, and uses thereof
TW202448928A (zh) 2023-03-02 2024-12-16 美商艾羅伊治療公司 抗cd22抗體及其用途
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024200854A1 (en) 2023-03-31 2024-10-03 Alk-Abelló A/S Allergen binding antibodies suitable for treating tree pollen allergies
WO2024220256A1 (en) 2023-04-18 2024-10-24 Qlsf Biotherapeutics, Inc. Antibodies binding to ly6g6d
WO2025007063A1 (en) 2023-06-30 2025-01-02 Avidity Biosciences, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
TW202513801A (zh) 2023-07-28 2025-04-01 美商雷傑納榮製藥公司 用於治療龐貝氏症之抗ＴｆＲ：ＧＡＡ及抗ＣＤ６３：ＧＡＡ插入
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
TW202515919A (zh) 2023-09-01 2025-04-16 比利時商艾托斯比利時公司 抗ｔｒｅｍ２抗體及使用方法
WO2025054181A1 (en) 2023-09-05 2025-03-13 Seagen Inc. Targeted degrader molecules and ligand drug conjugates thereof
WO2025059215A1 (en) 2023-09-12 2025-03-20 Aadigen, Llc Methods and compositions for treating or preventing cancer
TW202517301A (zh) 2023-10-06 2025-05-01 美商思進公司 用ｂ７－ｈ４抗體－藥物結合物治療晚期實體腫瘤之方法
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use
WO2025104604A1 (en) 2023-11-14 2025-05-22 Janssen Pharmaceuticals, Inc. Anti-respiratory syncytial virus antibodies and uses thereof
WO2025128343A1 (en) 2023-12-11 2025-06-19 Just-Evotec Biologics, Inc. Protein expression using trans-splicing and split selectable markers
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025133694A1 (en) 2023-12-20 2025-06-26 argenx BV Fcrn/hsa-binding molecules and methods of use
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025155877A2 (en) 2024-01-18 2025-07-24 The Regents Of The University Of California Antibodies binding to pad4 and uses thereof
WO2025184211A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibody drug conjugates
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
US20250361297A1 (en) 2024-03-12 2025-11-27 Adaptam Therapeutics, S.L. Anti- siglec-15 binding molecules and methods of use
WO2025217101A2 (en) 2024-04-09 2025-10-16 Amgen Inc. Agonistic anti-il-2rbg heavy‑chain antibodies
WO2025235357A1 (en) 2024-05-06 2025-11-13 Rondo Therapeutics, Inc. Bispecific antibodies that bind to cd28 and nectin-4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
AU4116793A (en) * 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
AU5098393A (en) * 1992-08-14 1994-03-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Recombinant toxin with increased half-life

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115380217A (zh) * 2020-04-08 2022-11-22 豪夫迈·罗氏有限公司 大分子非特异性清除测定
CN115380217B (zh) * 2020-04-08 2025-12-05 豪夫迈·罗氏有限公司 大分子非特异性清除测定

Also Published As

Publication number Publication date
AU1985097A (en) 1997-10-10
JP2000507816A (ja) 2000-06-27
EP0904107A1 (en) 1999-03-31
WO1997034631A1 (en) 1997-09-25
ATE279947T1 (de) 2004-11-15
AU728657B2 (en) 2001-01-18
DE69731289D1 (de) 2004-11-25
JP4046354B2 (ja) 2008-02-13
EP0904107B1 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
CA2249195A1 (en) Immunoglobin-like domains with increased half lives
US6277375B1 (en) Immunoglobulin-like domains with increased half-lives
AU682141B2 (en) Bispecific antibody heterodimers
US6083478A (en) Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 Immunoconjugates, and uses thereof
CA2038279C (en) Cd25 binding molecules
DE69519101T2 (de) Mhc-komplexe und ihre verwendung
AU729672B2 (en) MHC complexes and uses thereof
US7459544B2 (en) Nucleic acids encoding B7-2 fusion proteins
CA2210751C (en) Anti-cd6 monoclonal antibodies and their uses
US20050196402A1 (en) CTLA4-Cy4 fusion proteins
CA2118508A1 (en) Recombinant production of immunoglobulin-like domains in prokaryotic cells
DE3855869T2 (de) Verfahren und Zubereitungen für die Verwendung von HIV-env-Polypeptiden und Antikörpern
EP1340769B1 (en) CD4-gamma2 and CD4-IgG2 chimeras
EP2025345A1 (en) KIM-1 antagonists and use to modulate immune system
US7070991B2 (en) Cells expressing a CD4-IgG2 chimeric heterotetramer
US20030211470A1 (en) CD4-IgG2-based salvage therapy of HIV-1 infection
US6342586B1 (en) Non-peptidyl moiety-conjugated CD4-gamma2 and CD4-IgG2 immunoconjugates and uses thereof
HK1059789B (en) Cd4-gamma2 and cd4-lgg2 chimeras

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued